請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4938
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李繼忠 | |
dc.contributor.author | Hsuan Kuo | en |
dc.contributor.author | 郭璇 | zh_TW |
dc.date.accessioned | 2021-05-15T17:50:28Z | - |
dc.date.available | 2014-09-12 | |
dc.date.available | 2021-05-15T17:50:28Z | - |
dc.date.copyright | 2014-09-12 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-19 | |
dc.identifier.citation | Bacon NJ, Ehrhart NP, Dernell WS, et al. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). J Am Vet Med Assoc 232: 1504-1510, 2008.
Baum B, Meneses F, Kleinschmidt S, et al. Age-related histomorphologic changes in the canine gastrointestinal tract: a histologic and immunohistologic study. World J Gastroenterol 13: 152-157, 2007. Cameron DA, Massie C, Kerr G, et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89: 1837-1842, 2003. Chun R. Lymphoma: Which Chemotherapy Protocol and Why? Top Companion Anim Med 24: 157-162, 2009. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 14: 120-124, 2000. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 11: 279-283, 1997. Colleoni M, Price K, Castiglione-Gertsch M, et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 11: 1693-1700, 1998. Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 291: 998-1000, 1974. Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6: 669-677, 2005. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 16: 704-709, 2002. Gao B, Klumpen HJ, Gurney H. Dose calculation of anticancer drugs. Expert Opin Drug Metab Toxicol 4: 1307-1319, 2008. Greenlee PG, Filippa DA, Quimby FW, et al. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 66: 480-490, 1990. Gupte M, Tuck AN, Sharma VP, et al. Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator. PLoS One 8: e74071, 2013. Hahn KA, Richardson RC, Hahn EA, et al. Diagnostic and prognostic importance of chromosomal aberrations identified in 61 dogs with lymphosarcoma. Vet Pathol 31: 528-540, 1994. Hofheinz RD, Heinemann V, von Weikersthal LF, et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer 107: 1678-1683, 2012. Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 44: 388-400, 1998. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844-1852, 1997. Hosoya K, Kisseberth WC, Lord LK, et al. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma. J Vet Intern Med 21: 1355-1363, 2007. Jagielski D, Lechowski R, Hoffmann-Jagielska M, et al. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs(1998-2000). J Vet Med A Physiol Pathol Clin Med 49: 419-424, 2002. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 7: 289-295, 1993. Khanna C, Lund EM, Redic KA, et al. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 213: 985-990, 1998. Kiupel M, Teske E, Bostock D. Prognostic factors for treated canine malignant lymphoma. Vet Pathol 36: 292-300, 1999. Koschny R, Gotthardt D, Koehler C, et al. Diarrhea is a positive outcome predic- tor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 84: 6-13, 2013. MacEwen EG, Hayes AA, Matus RE, et al. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981). J Am Vet Med Assoc 190: 564-568, 1987. Marconato L, Stefanello D, Valenti P, et al. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. J Am Vet Med Assoc 238: 480-485, 2011. Marconato L, Zini E, Lindner D, et al. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 238: 1004-1010, 2011. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91: 2246-2257, 2001. Milano G, Etienne MC, Rene ́e N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12: 1291–1295, 1994. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 15: 348-354, 2001. Myers NC 3rd, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 11: 333-339, 1997. Owen L. TNM classification of tumors in domestic animals. Geneva: WHO: 46–47, 1980. Poikonen P, Saarto T, Lundin J, et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 11: 1763-1766, 1999. Price GS, Page RL, Fischer BM, et al. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med 5: 259-262, 1991. Rankin EM, Mill L, Kaye SB, et al. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 65: 275-281, 1992. Saarto T, Blomqvist C, Rissanen P, et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75: 301-305, 1997. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59: 287–290, 1989. Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 20: 948-954, 2006. Sorenmo K, Overley B, Krick E, et al. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Vet Comp Oncol 8: 196-208, 2010. Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer 105: 206-211, 2011. Thyss A, Milano G, Rene ́e N, et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16: 64-66, 1986. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23: 1190-1197, 2012. Vail DM, Kisseberth WC, Obradovich JE, et al. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Exp Hematol 24: 807-815, 1996. Valerius KD, Ogilvie GK, Mallinckrodt CH, et al. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 210: 512-516, 1997. Vaughan A, Johnson JL and Williams LE. Impact of chemotherapeutic dose intensity and hematologic toxicity on first progression free survival durationin dogs with lymphoma treated with a chemoradiotherapy protocol. Journal of Veterinary Internal Medicine 21: 1332–1339, 2007. Vial DM, Pinkerton ME, Young KM. Hematopoietic tumors. In: Withrow SJ, Vail DM, Page RL, ed. Withrow and MacEwen's small animal clinical oncology. 5th ed. Elsevier, Maryland Heights, 619-621, 2013. Veterinary Cooperative Oncology Group (VCOG). Veterinary Cooperative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2: 195-213, 2004. Zemann BI, Moore AS, Rand WM, et al. A combination che- motherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 12: 465-470, 1998 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4938 | - |
dc.description.abstract | 本研究目的為探討犬多中心型淋巴瘤的化療毒性以及療效間的相關性。六十九隻罹患多中心型淋巴瘤且在國立台灣大學附設動物醫院接受以CHOP療程為基礎的化學治療的犬隻的病歷被回顧,並且分析其中骨髓毒性以及消化道毒性對於疾病進展時間(Time to tumor progression, TTP),總存活時間(Overall survival time, OST),以及短期的腫瘤抑制效果的影響。嗜中性球低點小於5000/μl可增進OST (P =0.045)。出現食慾不振、嘔吐、腹瀉其中一種消化道毒性或者僅出現嘔吐皆可增加TTP 及OST (P =0.042, 0.007對於TTP; 0.023, <0.001對於OST)。出現毒性分級三或四的腹瀉會降低TTP及OST (P =0.034, 0.017)。年齡超過十歲較不容易出現毒性分級低的消化道毒性,同時也有較不理想的治療成果。在單次治療後出現嗜中性球低下或者消化道毒性,會增加該次治療成為有效治療而非無效治療的可能性,顯示毒性以及短期療效之間存在正向關係。本研究的結果支持依據毒性反應來調整藥物劑量的概念,但是必須靠前瞻性研究才能建立起完善的依據毒性做劑量調整的規範。 | zh_TW |
dc.description.abstract | This study was aimed at investigating the correlation between chemotherapy toxicity and antitumor efficacy in canine multicentric lymphoma. Medical records of 69 dogs with multicentric lymphoma received CHOP-based chemotherapy at National Taiwan University Veterinary Hospital were reviewed, and impact of bone marrow toxicity and GI toxicity on time to tumor progression (TTP), overall survival time (OST), and short-term tumor-killing effect was evaluated. Neutrophil nadir lower than 5000 /μl improved OST (P =0.045). Presence of GI signs, including anorexia, vomiting, and diarrhea, or presence of only vomiting improved TTP and OST (P =0.042, 0.007 for TTP; 0.023, <0.001 for OST). Presence of diarrhea of grade 3 or 4 decreased TTP and OST (P =0.034, 0.017). More than 10 years old was associated with less low-grade GI toxicities and less favorable outcome. Occurrence of neutropenia or GI toxicity after a treatment increased the like hood of effective treatment over ineffective treatment, implying a positive relationship between toxicity and short-term efficacy. The results of the study supported the concept of toxicity-adjusted dosing, but prospective trials are warranted to develop a sophisticated toxicity-adjusted dosing regimen. | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T17:50:28Z (GMT). No. of bitstreams: 1 ntu-103-R00643010-1.pdf: 2853938 bytes, checksum: b412e58941a4fe39a23cff20f8a3acd4 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | Abstract --------------------------------------------------------------------------------------------- I
Table of contents -------------------------------------------------------------------------------- II List of Tables ------------------------------------------------------------------------------------ VI List of Figures --------------------------------------------------------------------------------- VIII 1. Introduction ------------------------------------------------------------------------------------- 1 2. Literature Review ------------------------------------------------------------------------------ 3 2.1 Canine multicentric lymphoma and CHOP-based chemotherapy ------------------ 3 2.2 Correlation between toxicity and antitumor efficacy of chemotherapy ------------ 4 2.2.1 Related research in human medicine --------------------------------------------- 4 2.2.2 Related research in veterinary medicine ----------------------------------------- 8 3. Aim --------------------------------------------------------------------------------------------- 11 4. Materials and Methods ----------------------------------------------------------------------- 12 4.1 Patient selection -------------------------------------------------------------------------- 12 4.2 Chemotherapy protocol ----------------------------------------------------------------- 12 4.3 Diagnosis and staging ------------------------------------------------------------------- 14 4.4 Response and toxicity assessment ----------------------------------------------------- 15 4.5 Prognostic factors ------------------------------------------------------------------------ 17 4.6 Long-term analysis ----------------------------------------------------------------------- 18 4.7 Short-term analysis ---------------------------------------------------------------------- 20 4.8 Statistics ----------------------------------------------------------------------------------- 22 5. Results ----------------------------------------------------------------------------------------- 24 5.1 Patient characteristics ------------------------------------------------------------------- 24 5.2 Response and toxicity ------------------------------------------------------------------- 25 5.3 Prognostic factors ------------------------------------------------------------------------ 26 5.4 Long-term analysis ----------------------------------------------------------------------- 28 5.5 Short-term analysis ---------------------------------------------------------------------- 34 6. Discussion ------------------------------------------------------------------------------------- 36 6.1 Patient characteristics, overall response, and toxicity profile ---------------------- 36 6.2 Prognostic factors ------------------------------------------------------------------------ 37 6.3 Long-term analysis ----------------------------------------------------------------------- 38 6.3.1 Neutropenia and efficacy --------------------------------------------------------- 38 6.3.2 GI toxicity and efficacy ---------------------------------------------------------- 41 6.3.3 Timing of toxicity during the protocol and efficacy -------------------------- 42 6.3.4 Toxicity after different drugs and efficacy ------------------------------------- 43 6.3.5 Frequency of toxicity and efficacy ---------------------------------------------- 44 6.3.6 Age and GI toxicity --------------------------------------------------------------- 45 6.3.7 Confounding factors -------------------------------------------------------------- 46 6.3.8 Multivariate analysis -------------------------------------------------------------- 46 6.8 Short-term analysis ---------------------------------------------------------------------- 47 6.9 Toxicity-adjusted dosing --------------------------------------------------------------- 48 6.10 Limitations ------------------------------------------------------------------------------ 50 7. Conclusion ------------------------------------------------------------------------------------- 52 8. References ------------------------------------------------------------------------------------- 54 | |
dc.language.iso | en | |
dc.title | CHOP療程為基礎的化學治療在犬多中心型淋巴瘤的毒性反應以及腫瘤治療效果間的相關性 | zh_TW |
dc.title | Correlation between Toxicity and Antitumor Efficacy of CHOP-based Chemotherapy in Canine Multicentric Lymphoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭宏昇,廖泰慶,林辰栖,李雅珍 | |
dc.subject.keyword | 化學治療,骨髓毒性,消化道毒性,淋巴瘤,CHOP,犬, | zh_TW |
dc.subject.keyword | chemotherapy,bone marrow toxicity,GI toxicity,lymphoma,CHOP,dogs, | en |
dc.relation.page | 103 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-08-20 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
顯示於系所單位: | 臨床動物醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 2.79 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。